Crescendo Bioscience has announced that Vectra DA, a first-in-class multi-biomarker blood test, can track rheumatoid arthritis activity and provide physicians with a measure to determine whether patients are responding to therapy.
Its studies have confirmed that Vectra DA has the ability to quantify and track rheumatoid arthritis activity, and can discriminate between low disease activity and remission within two weeks.
Vectra DA also predicts progressive joint damage and common co-morbid conditions in patients with rheumatoid arthritis.
Stephen Paget, physician-in-chief emeritus at the Hospital for Special Surgery in New York, said that the data indicated that Vectra DA can provide physicians with a molecular monitoring system for rheumatoid arthritis activity.
Related
Related Companies
